Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.66 |
| ▸ | KIT | P10721 | 3/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.66 |
| ▸ | AXL | P30530 | 2/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.61 |
| ▸ | RET | P07949 | 3/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.61 |
| ▸ | FLT1 | P17948 | 2/20 | 0.61 |
| ▸ | FLT4 | P35916 | 2/20 | 0.61 |
| ▸ | ABL1 | P00519 | 2/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | ERN1 | O75460 | 1/20 | 0.61 |
| ▸ | STK10 | O94804 | 1/20 | 0.61 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | BCR | P11274 | 1/20 | 0.61 |
| ▸ | NQO2 | P16083 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895271 | 0.93 | KDR (0.64) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL1901501 | 0.92 | KDR (0.67) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL1896412 | 0.92 | KDR (0.67) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL14423802 | 0.92 | KDR (0.62) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL1889665 | 0.91 | KDR (0.64) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL1250601 | 0.91 | KDR (0.64) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL5208548 | 0.91 | KDR (0.79) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL1898773 | 0.91 | KDR (0.63) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL1890996 | 0.90 | KDR (0.60) | KDRPDGFRAKITFGFR2AXL | |
| SCHEMBL6796519 | 0.90 | KDR (0.62) | KDRPDGFRAKITFGFR2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110293615-A1 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-12-01 | — | — | US | claimed |
| EP-2281901-A2 | Anti-tumour pharmaceutical composition with angiogenesis inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-02-09 | — | — | EP | claimed |
| EP-2248804-A1 | COMBINED USE OF ANGIOGENESIS INHIBITOR AND TAXANE | Eisai R&D Management Co., Ltd. (JP) | 2010-11-10 | — | — | EP | claimed |
| US-20100239688-A1 | COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND ANTI-TUMOR PLATINUM COMPLEX | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-23 | — | — | US | claimed |
| EP-2218712-A1 | COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND ANTI-TUMOR PLATINUM COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2010-08-18 | — | — | EP | claimed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | claimed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| EP-2116246-A1 | COMPOSITION FOR TREATMENT OF PANCREATIC CANCER | Eisai R&D Management Co., Ltd. (JP) | 2009-11-11 | — | — | EP | claimed |
| US-20090264464-A1 | ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-10-22 | — | — | US | claimed |
| US-20090247576-A1 | ANTI-TUMOR AGENT FOR MULTIPLE MYELOMA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-10-01 | — | — | US | claimed |
| US-20090203693-A1 | THERAPEUTIC AGENT FOR LIVER FIBROSIS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | claimed |
| EP-2065372-A1 | ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER | Eisai R&D Management Co., Ltd. (JP) | 2009-06-03 | — | — | EP | claimed |
| EP-2036557-A1 | ANTITUMOR AGENT FOR THYROID CANCER | Eisai R&D Management Co., Ltd. (JP) | 2009-03-18 | — | — | EP | claimed |
| US-20090053236-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-26 | — | — | US | claimed |
| EP-1964837-A1 | ANTI-TUMOR AGENT FOR MULTIPLE MYELOMA | Eisai R&D Management Co., Ltd. (JP) | 2008-09-03 | — | — | EP | claimed |
| EP-1949902-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-07-30 | — | — | EP | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239688-A1 | COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND ANTI-TUMOR PLATINUM COMPLEX | PGF, VEGFA, FLT4 | KDR 16/4885PDGFRA 382/4885KIT 191/4885 |
| US-20090247576-A1 | ANTI-TUMOR AGENT FOR MULTIPLE MYELOMA | FGFR3, MCTS1, TP53 | KDR 2806/4885PDGFRA 3371/4885KIT 1782/4885 |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | KDR 2/4885PDGFRA 13/4885KIT 275/4885 |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | VEGFA, FLT4, MKI67 | KDR 6/4885PDGFRA 83/4885KIT 59/4885 |
| US-20110293615-A1 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor | KIT, FLT4, KDR | KDR 3/4885PDGFRA 10/4885KIT 1/4885 |
| US-20090203693-A1 | THERAPEUTIC AGENT FOR LIVER FIBROSIS | HDGF, MMP1, FABP1 | KDR 3906/4885PDGFRA 150/4885KIT 846/4885 |
| US-20090264464-A1 | ANTITUMOR AGENT FOR UNDIFFERENTIATED GASTRIC CANCER | FGFR2, FGFR3, FGF2 | KDR 340/4885PDGFRA 166/4885KIT 181/4885 |
| US-20090053236-A1 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR | KIT, FLT4, KDR | KDR 3/4885PDGFRA 10/4885KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.